Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [ChIP-Seq, ATAC-Seq]

ABSTRACT: BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [ChIP-Seq, ATAC-Seq]

PROVIDER: PRJNA765322 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [RNA-Seq]

Project description:BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [RNA-Seq]

| PRJNA765320 | ENA

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

Project description:BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

| PRJNA765317 | ENA

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [RNA-Seq]

Project description:Targeting chromatin binding proteins and modifying enzymes can concomitantly affect tumor cell proliferation and survival, as well as enhance anti-tumor immunity and augment cancer immunotherapies. By screening a small molecule library of epigenetics-based therapeutics, BET bromodomain inhibitors (BETi) were identified as agents that sensitize tumor cells to the anti-tumor activity of CD8+ T-cells. BETi modulated tumor cells to be sensitized to the cytotoxic effects of the pro-inflammatory cytokine TNF. By preventing the recruitment of BRD4 to p65-bound cis-regulatory elements, BETi suppressed the induction of inflammatory gene expression, including the key NF-B target genes BIRC2 (cIAP1) and BIRC3 (cIAP2). Disruption of pro-survival NF-B signaling by BETi led to unrestrained TNF-mediated activation of the extrinsic apoptotic cascade and tumor cell death. Administration of BETi in combination with T-cell bispecific (TCB) antibodies increased bystander killing of tumor cells and enhanced tumor growth inhibition in vivo in a TNF-dependent manner. This novel epigenetic mechanism of immunomodulation may guide future use of BETi as adjuvants for immune oncology agents.

2021-09-24 | GSE184589 | GEO

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [ChIP-Seq, ATAC-Seq]

2021-09-24 | GSE184591 | GEO

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-09-24 | GSE184592 | GEO

Cyclin-dependent kinase 9 is a therapeutic target for anti-TNF resistant inflammatory bowel disease

Project description:The treatment of auto-inflammatory diseases is often limited by resistance to single cytokine blockade, primarily anti-TNF antibodies. This is a particularly important cause of treatment failure in inflammatory bowel disease (IBD). The transcription factor T-bet is a critical regulator of intestinal homeostasis and is genetically linked to mucosal inflammation by causal variation in its binding sites. However, transcription factors such as T-bet are difficult to target therapeutically. Using CDK9 inhibitors, we show that modulation of P-TEFb (cyclinT1/CDK9), a transcriptional elongation factor downstream of T-bet, potently represses genes responsible for pro-inflammatory signalling, and in particular genes regulated by T-bet. Remarkably, CDK9 inhibition targets genes that are highly expressed in anti-TNF resistant IBD and that predict non-response to anti-TNF therapy. Collectively, our findings reveal CDK9 as a potential target in anti-TNF resistant IBD, which has the potential for rapid translation to the clinic.

2022-06-17 | GSE172372 | GEO

Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [RNA-Seq]

Project description:Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [RNA-Seq]

| PRJNA778073 | ENA

T-bet-Eomes [ChIP-Seq]

Project description:T-bet-Eomes [ChIP-Seq]

| PRJNA706661 | ENA

Effect of anti-TNF/IL-6 NANOBODY® VHH, Humira, Sylvant, TNF, IL6 and TNF+IL6 in RA-FLS/T cell cocultures

Project description:Additive effects of TNF and IL-6 were evaluated in cell-based model for rheumatoid arthritis (RA) and then compared to treatment with anti-TNF/IL-6 NANOBODY® VHH, Humira and Sylvant by RNA-seq

2022-12-31 | GSE200291 | GEO

Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.

Project description:Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.

| PRJNA683080 | ENA